|
ETN n=156 n (%) |
IFX n=32 n (%) |
ETN VS. IFX P-value |
ADA n=126 n (%) |
ETN VS. ADA P-value |
|
|---|---|---|---|---|---|
| 12 months after anti-TNF initiation | |||||
| Dose escalation | 0 (0.0) | 12 (37.5) | <0.001 | 2 (1.6) | 0.199 |
| Dose escalation and/or DMARD intensification | 17 (10.9) | 13 (40.6) | <0.001 | 18 (14.3) | 0.468 |
| Dose escalation and/or DMARD and/or glucocorticoid intensification | 25 (16.0) | 15 (46.9) | <0.001 | 35 (27.8) | 0.019 |
| Discontinue anti-TNF and switch to another biologic | 7 (4.5) | 1 (3.1) | 1.000 | 12 (9.5) | 0.101 |
| Discontinue anti-TNF but no switch | 6 (3.8) | 0 (0.0) | 0.592 | 6 (4.8) | 0.772 |
| Dose de-escalation | 1 (0.6) | 0 (0.0) | 1.000 | 0 (0.0) | 1.000 |
| 18 months after anti-TNF initiation | n=102 | n=25 | n=90 | ||
| Dose escalation | 0 (0.0) | 8 (32.0) | <0.001 | 2 (2.2) | 0.218 |
| Dose escalation and/or DMARD intensification | 11 (10.8) | 10 (40.0) | 0.001 | 17 (18.9) | 0.151 |
| Dose escalation and/or DMARD and/or glucocorticoid intensification | 16 (15.7) | 11 (44.0) | 0.005 | 31 (34.4) | 0.004 |
| Discontinue anti-TNF and switch to another biologic | 6 (5.9) | 1 (4.0) | 1.000 | 20 (22.2) | 0.001 |
| Discontinue anti-TNF but no switch | 2 (2.0) | 0 (0.0) | 1.000 | 6 (6.7) | 0.150 |
| Dose de-escalation | 2 (2.0) | 0 (0.0) | 1.000 | 1 (1.1) | 1.000 |